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Klebsiella pneumoniae is a leading cause of antimicrobial-resistant (AMR) healthcare-
associated infections, neonatal sepsis and community-acquired liver abscess, and is asso-
ciated with chronic intestinal diseases. Its diversity and complex population structure pose
challenges for analysis and interpretation of K. pneumoniae genome data. Here we introduce
Kleborate, a tool for analysing genomes of K. pneumoniae and its associated species complex,
which consolidates interrogation of key features of proven clinical importance. Kleborate
provides a framework to support genomic surveillance and epidemiology in research, clinical
and public health settings. To demonstrate its utility we apply Kleborate to analyse publicly
available Klebsiella genomes, including clinical isolates from a pan-European study of
carbapenemase-producing Klebsiella, highlighting global trends in AMR and virulence as
examples of what could be achieved by applying this genomic framework within more sys-
tematic genomic surveillance efforts. We also demonstrate the application of Kleborate to
detect and type K. pneumoniae from gut metagenomes.
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K lebsiella pneumoniae bacteria commonly colonize themammalian gut, but are also recognized as a major publichealth threat due to their ability to cause severe infections
in healthcare settings and their association with antimicrobial
resistance (AMR)1,2. Reports of K. pneumoniae gut colonization
frequencies vary by country and demographics; prevalence rates
as low as 4% and as high as 87% have been reported3–6. K.
pneumoniae colonization is implicated in chronic diseases of the
gastrointestinal tract including inflammatory bowel disease and
colorectal cancer7. There is also a growing body of evidence
highlighting colonization as a reservoir for extraintestinal infec-
tions (urinary tract infection, pneumonia, wound or surgical site
infections, sepsis) in vulnerable individuals such as neonates, the
elderly, immunocompromized and hospitalized patients8. Treat-
ment of healthcare-associated (HA) K. pneumoniae infections is
often limited by multidrug resistance (MDR) resulting from the
accumulation of horizontally acquired AMR genes and mutations
in core genes2. Treatment is further complicated by increasing
frequencies of strains producing extended-spectrum β-lactamases
(ESBL) and/or carbapenemases, prompting increased reliance on
colistin and β-lactam/β-lactamase inhibitor combinations9,10. The
World Health Organization has accordingly prioritized K. pneu-
moniae as a target for new drugs and therapies11.
Outside healthcare settings, K. pneumoniae is also recognized
as a causative agent of community-acquired infections including
urinary tract infection and pneumonia, but also invasive infec-
tions such as pyogenic liver abscess, endophthalmitis and
meningitis12,13. Invasive community-acquired infections are
generally associated with so-called hypervirulent K. pneumoniae
(hvKp) and are most commonly reported in East and Southeast
Asia, or in individuals with East Asian ancestry12. Features
associated with hvKp include a K1, K2 or K5 polysaccharide
capsule and horizontally acquired virulence factors encoding the
siderophores aerobactin (Iuc) and salmochelin (Iro), the geno-
toxin colibactin (Clb), and a hypermucoid phenotype (conferred
by the rmpADC locus)14–18. HvKp are rarely MDR and most
strains remain susceptible to drugs except ampicillin, to which K.
pneumoniae are intrinsically resistant due to the chromosomally
encoded β-lactamase SHV19. However, there have been increas-
ing reports of hvKp carrying AMR plasmids and co-occurrence of
AMR and virulence determinants in non-hvKp isolates. The
convergence of AMR and virulence in K. pneumoniae potentiates
invasive and difficult-to-treat infections, and at least one fatal
outbreak has been documented in China where carbapenemase-
producing hvKp are increasingly common20–24.
Research conducted in the pre-genomic era characterized 77
distinct capsular (K) serotypes25, nine O types26 and variable
AMR profiles amongst the K. pneumoniae population27,28, indi-
cating a diverse genetic and phenotypic landscape15,29. In recent
years, genomic studies have provided key insights into the
population structure of K. pneumoniae (recently summarized in
Wyres et al.16), revealing hundreds of deep-branching phyloge-
netic lineages comprising sequence types (STs) or clonal groups
(CGs) defined by the seven-gene multi-locus sequence typing
(MLST) scheme29. Some of these correspond to lineages (i.e. STs
and CGs) that have accumulated large numbers of AMR genes
that have become globally distributed (e.g. CG258, CG15, ST307);
these are dubbed MDR clones and have been linked with HA
infections and hospital outbreaks worldwide30. Others carry a
high load of virulence genes (e.g. CG23, CG65, CG86) and are
recognized as hvKp associated with community-acquired infec-
tions. Further distinguishing MDR from hvKp clones are their K
and O antigen profiles, with the former displaying a diverse range
of K and O biosynthesis loci as a result of homologous recom-
bination between strains, while hvKp rarely deviate from the K1,
K2 or K5 types16.
Importantly, genomic characterization of clinical isolates
identified as K. pneumoniae via biochemical tests or mass spec-
trometry (MALDI-TOF) has revealed the existence of multiple
related species and subspecies, which together form the K.
pneumoniae species complex (KpSC). These differ by 3-4%
nucleotide divergence across core chromosomal genes, but share
the same pool of AMR and virulence genes16. Infections and
outbreaks caused by other KpSC members have been reported but
they generally account for a significantly lower disease burden
than K. pneumoniae (10–20%)19,31,32. Genomics has also clarified
that the two K. pneumoniae subspecies originally defined by
distinct and unusual disease manifestations (subsp. rhinoscler-
omatis which causes a progressive and chronic granulomatous
infection known as rhinoscleroma, and subsp. ozaenae which
causes atrophic rhinitis or ozena) actually represent CGs of K.
pneumoniae (CG3 and CG90)15. Like hvKp clones, these strains
also express specific capsule types (K3, K4 and K5) alongside
aerobactin and another acquired siderophore, yersiniabactin
(Ybt)16.
Due to its clinical importance and increasing AMR, K. pneu-
moniae is increasingly the focus of surveillance efforts and
molecular epidemiology studies. The sheer volume of clinically
relevant molecular targets renders whole-genome sequencing
(WGS) the most cost-efficient characterization approach, how-
ever extracting and interpreting clinically important features is
challenging. To address this, we have developed Kleborate, a
genotyping tool designed specifically for K. pneumoniae and the
associated species complex, which consolidates detection and
genotyping of key virulence and AMR loci alongside species,
lineage (ST) and predicted K and O antigen serotypes directly
from genome assemblies. Here we describe Kleborate and
demonstrate its utility by application to publicly available data-
sets. First, we show that Kleborate can rapidly recapitulate and
augment the key findings from a recent large-scale European
genomic surveillance study33. Next, we apply Kleborate to a
curated collection of 13,156 publicly available WGS to further
showcase its utility and derive novel insights into the global
epidemiology of Klebsiella AMR, virulence and convergence.
Finally, we show that Kleborate can also be applied to detect
clinically relevant genotypes from metagenome-assembled gen-
omes (MAGs).
Results
Integrated genomic framework and genotyping tool. Our goal
was to develop a single tool that can rapidly extract genotype
information that is clinically relevant to K. pneumoniae and other
members of the species complex in order to support genomic
epidemiology and surveillance. We have previously reported
genotyping schemes for the acquired K. pneumoniae virulence
loci ybt, clb, iuc and iro34,35 (whose detection and typing is
implemented in early versions of Kleborate), and also K and O
antigen typing implemented in the software Kaptive36. Here we
expand the Kleborate framework to include additional features
including taxonomic assignment to species and subspecies,
assignment to lineages via seven-locus MLST, detection and
genotyping of the rmp hypermucoidy locus and the rmpA2 gene,
and identification of AMR determinants (mutations and hor-
izontally acquired genes, including assignment of SHV β-
lactamase alleles as either ESBL, β-lactamase inhibitor resis-
tance, or intrinsic ampicillin resistance only, see “Methods” and
Supplementary note 3). Kleborate can optionally call Kaptive for
K/O antigen prediction.
Unlike generic AMR or virulence typing tools, we include only
genetic features for which there is strong evidence of an
associated phenotype in K. pneumoniae that has confirmed
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clinical relevance based on published experimental data (Table 1).
These are reported in a manner that facilitates interpretation,
including summarizing virulence and AMR genotypes into scores
that reflect escalating clinical risk in K. pneumoniae infections.
Kleborate features are summarized in Table 1 and methodological
details for genotyping are provided in “Methods”. For a typical
5.5 Mbp genome, a Kleborate run including AMR typing takes
<10 s on a laptop, while robust K and O serotype prediction using
Kaptive36 adds an additional ~1 min. Results are output in tab-
delimited format, making it easy to integrate Kleborate into
existing workflows.
Species and subspecies assignment. The taxonomy of Klebsiella is
rapidly evolving, with several new species and subspecies recently
identified37–39. As a consequence, many genomes in public
databases are incorrectly assigned. We therefore introduced a
custom approach for rapid and accurate species and subspecies
identification for Klebsiella, based on Mash distances40 to a tax-
onomically curated genome set (representative tree in Supple-
mentary Fig. 1a, b), avoiding the need for users to download large
reference genome databases (see “Methods”). This approach was
validated using a set of n= 285 diverse clinical isolates and
compared with species assignments based on the read-based
taxonomic classifier Kraken2 (details in Supplementary Note 1,
Supplementary Data 1, Supplementary Fig. 1).
Virulence and AMR scores. Genomes are scored according to the
clinical risk associated with the AMR and virulence loci that are
detected (see “Methods”). Here we take advantage of the structured
distribution of AMR and virulence determinants within the K.
pneumoniae population14 to summarize the genotyping data with
simple numerical summary scores that reflect the accumulation of
loci contributing to clinically relevant AMR or hypervirulence:
virulence scores range from 0 to 5, depending on the presence of key
loci associated with increasing risk (yersiniabactin < colibactin <
aerobactin, see the detailed rationale in “Methods”); resistance scores
range from 0 to 3, based on detection of genotypes warranting
escalation of antimicrobial therapy (ESBL < carbapenemase < car-
bapenemase plus colistin resistance, see Table 1). These simple
numerical scores facilitate downstream analyses including trend
detection. For example, analysis of a non-redundant subset of 9,705
publicly available K. pneumoniae genomes (see below, Supplemen-
tary Data 2) showed increasing AMR and virulence scores over time
(barplots in Fig. 1a, b). The virulence and resistance scores were
correlated not only with the prevalence of individual components
that contribute to the scores, but also with other components that
are co-distributed in the population (lines in Fig. 1a, b). For example,
the frequencies of rmpADC and rmpA2 loci over time were corre-
lated with the virulence score (Fig. 1a); and the resistance score was
correlated with the mean number of acquired AMR genes and
associated drug classes (excluding ESBLs, carbapenemases and
colistin which contribute to the score) (Fig. 1c). Consistent with this,
genomes with resistance scores >0 (assigned based on the presence
of ESBL and/or carbapenemase genes) typically carry many addi-
tional AMR genes conferring resistance to multiple drug classes
(Fig. 1d, e). The distribution of virulence scores in this genome set
differed by isolate source, and skewed higher in human clinical
specimens (mean 0.86) compared to human gut carriage (mean 0.53,
p < 1 × 10−15), animal (mean 0.39, p < 1 × 10−11), or environmental
samples (mean 0.49, p < 1 × 10−8) (see Supplementary Fig. 2). Iso-
lates from liver abscess (associated with hypervirulent K. pneumo-
niae) had particularly high scores (mean 3.8, median 5), reflecting
the presence of iuc as expected for this relatively rare infection type;
in contrast other infection types most commonly have scores of 0
(40–60%) or 1 (reflecting presence of ybt without iuc; 20–40%), as
expected for opportunistic K. pneumoniae infections. Notably, there
were also animal and environmental isolates with non-zero virulence
scores (5–25%), reflecting the cycling of K. pneumoniae between
ecological niches2. Reducing the data to key axes of virulence and
AMR also facilitates exploration of subpopulations associated with
AMR, virulence or convergence of both traits; such as specific K.
pneumoniae lineages or specimen types (see below). It is important
to note though that the scores summarize the detection of specific
genetic determinants, and are not direct predictions of clinical
virulence or antibiotic resistance.
Rapid genotyping of clinical isolates from a large-scale sur-
veillance study. We applied Kleborate to analyse all K. pneu-
moniae clinical isolate genomes deposited in RefSeq by the
EuSCAPE surveillance study (927 carbapenem-non-susceptible,
697 carbapenem-susceptible; see Supplementary Data 2)33. Kle-
borate rapidly and accurately reproduced key findings from the
original study, which were originally derived from multi-step
analyses comprising five independent tools and four independent
databases (each from a different public repository, one with
Table 1 Genome features reported by Kleborate.
Feature Description
Assembly quality Contig count, N50, largest contig, ambiguous bases
Identification Species16, multi-locus sequence typing (MLST)29,85 (if K. pneumoniae species complex)





• hypermucoidy loci rmpADC and rmpA2
Virulence score 0= no yersinabactin, colibactin or aerobactin; 1= yersiniabactin only; 2= yersiniabactin and colibactin (or colibactin
only); 3= aerobactin without yersiniabactin or colibactin; 4= aerobactin with yersiniabactin (no colibactin); 5=
yersiniabactin, colibactin and aerobactin
Serotype prediction wzi allele and associated K locus77 (default), Full K and O locus typing via Kaptive36 (optional)
AMR determinants (optional)
Acquired genes Total count, alleles grouped by drug class, truncations
Mutations in core genes SHV beta-lactamase (extended-spectrum beta-lactamase/ESBL or inhibitors)86, OmpK35/OmpK36 osmoporins41,42
(carbapenems), MgrB/PmrB57–59 (colistin), GyrA/ParC76 (fluoroquinolones)
Number of drug classes Excludes penicillins since resistance is intrinsic
Resistance score 1= ESBL; 2= Carbapenemase; 3=Carbapenemase plus colistin resistance; 0 otherwise
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additional manual curation): (i) 70.2% of carbapenem-non-
susceptible genomes (n= 651/927) carried carbapenemases,
mainly KPC-3, OXA-48, KPC-2 and NDM-1; (ii) these were
dominated by a few major clones, ST11, ST15, ST45, ST101,
ST258, and ST512; (iii) individual countries were associated with
specific carbapenemase/clone combinations (Fig. 2a). A detailed
comparison of the results reported by Kleborate versus those
reported in the original study is provided in Supplementary Note
2 and Supplementary Data 3.
In addition to the detection of carbapenemase genes, Kleborate
also identified porin defects, which are known to contribute to the
carbapenem-resistance phenotype41,42, in 36.5% of EuSCAPE
genomes (including 60% of those with carbapenemase genes and
19.9% of those without carbapenemase genes). These defects
included truncation/deletion of OmpK35 and/or OmpK36 (also
considered in the original study) as well as GD or TD insertions in
the OmpK36 β-strand loop41 (these insertions were not analysed
in the original study, but here were detected in 17.9% of genomes
including 18 with no porin deletion). Figure 3 shows meropenem
MICs stratified by combinations of porin defect and carbapene-
mase identified by Kleborate. OmpK mutations were associated
with elevation of meropenem MIC, although in the absence of a
carbapenemase gene the effect was only clinically significant (>2







































































































































Fig. 1 Relationships between Kleborate virulence and resistance scores and the prevalence of key virulence and antimicrobial resistance (AMR). Data
shown summarize Kleborate results for non-redundant set of 9705 publicly available K. pneumoniae genomes (Supplementary Data 2). a Barplot shows
mean virulence score per year (right y-axis), line plots show the prevalence of individual virulence loci per year (left y-axis). Ybt yersiniabactin, clb
colibactin, iuc aerobactin, iro salmochelin, rmpADC hypermucoidy rmp locus, rmpA2 rmpA2 gene. Spearman correlation coefficients (rs) between the mean
virulence score and prevalence of each locus are noted. P values from two-sided statistical testing: ybt= 2.2 × 10−16, clb= 0.74, iuc= 0.0002, iro= 0.68,
rmpADC= 0.005, rmpA2= 0.002. b Barplot shows mean resistance score per year (right y-axis) and line plots show the prevalence of carbapenemases
(carb), acquired colistin resistance genes (col gene), mutations in MgrB/PmrB (col mut) and genes conferring resistance to extended-spectrum β-lactams
(ESBL) (left y-axis). Spearman correlation coefficients (rs) between mean resistance score and prevalence of each resistance type are noted. P values: carb
= 8.3 × 10−6, col gene= 0.06, col mut= 0.05, ESBL= 5.56 × 10−5. c Mean number of acquired AMR genes and classes, over time. Spearman correlation
coefficients with mean resistance score are noted. P values: AMR genes= 0.001, AMR classes= 2.2 × 10−16. d Histograms showing total number of
acquired AMR classes predicted per genome, stratified by resistance score. e Histograms showing a total number of acquired AMR genes detected per
genome, stratified by resistance score. Spearman correlation coefficients are shown in a-c; significance levels are indicated with asterisks: *p < 0.01,
**p < 0.001.
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of OmpK36 (Fig. 3). Importantly, while carbapenemase genes
were clearly associated with an elevation in meropenem MIC,
there was variation depending on enzyme type. KPC and NDM
were each associated mean MIC above the clinical cut-off for
resistance (>8mg/mL) even in isolates with wildtype OmpK35
and OmpK36; however OXA and VIM enzymes on average were
associated with MICs above the insusceptible cut-off (>2mg/mL)
in wildtype OmpK35/OmpK36 isolates, and required the presence
of OmpK mutations to reach the resistance cut-off (>8mg/mL)
(Fig. 3). This highlights both (i) the importance of porin defects—
including the OmpK36 β-strand loop insertions—for full expres-
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Fig. 2 Kleborate genotyping results for European K. pneumoniae surveillance isolates. Data shown summarize Kleborate results for 927 carbapenem-
non-susceptible and 697 carbapenem-susceptible K. pneumoniae genomes from the EuSCAPE study (data included in Supplementary Data 2).
a Geographical and lineage distribution of carbapenemase genes. Each circle represents a genome, coloured by carbapenemase (see inset legend). Barplots
summarize the number of genomes from each K. pneumoniae lineage (top) and country (right), coloured by carbapenemase. b–c Cumulative prevalence of
(b) capsule (K) locus and (c) O antigen locus types, for carbapenem-non-susceptible (meropenem MIC > 2) isolates, ordered by overall prevalence. Thick
line indicates curve for whole data set; others give results separately for different United Nations geographical regions (see inset legend).
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complex nature of some AMRmechanisms, which extends beyond
mere presence or absence of a single acquired gene or mutation.
The rise in carbapenem-resistant K. pneumoniae infections in
hospitals and its associated morbidity and mortality43 has led to
increased interest in alternative control strategies such as
vaccines, phage therapy and antibody therapy, key targets for
which are the K and O surface antigens44–47. Kleborate
confidently identified K and O biosynthesis loci in 98.3% and
99.1% of EuSCAPE genomes, respectively, including 87 distinct K
loci and 11 distinct O loci (Supplementary Figs. 3 and 4).
Amongst carbapenem-non-susceptible isolates (meropenem MIC
> 2), 38 distinct K types were identified and the most common
were KL107 (n= 173), KL17 (n= 67), KL106 (n= 41), KL24 (n
= 35), KL15 (n= 19) and KL36 (n= 13). Seven distinct O types
were detected among these genomes, and the most common were
O2 (n= 294), O1 (n= 136) and O4 (n= 52). Overall, the data
suggest an intervention would need to be effective against six K
types or two O types in order to provide coverage of 80% of
carbapenem-resistant infections in Europe (Fig. 2b, c). However,
it is important to explore the impact of population structure on
these findings, specifically the impact of local clonal expansions.
Kleborate aides this type of analysis by providing ST and other
genotyping information alongside the K and O locus types, which
can be viewed in the context of geographic information. Doing so
revealed that each of the top three K loci was dominated by a
single ST (83.5% of KL107 were ST512; 93.0% of KL105 were
ST11; 91.4% of KL17 were ST101). Importantly, the vast majority
of ST512-KL107 genomes (75.3%) originated from Italy where
this ST is known to be locally circulating48,49, while 58% of ST11-
KL105 originated from Poland and Slovakia, and 56% of ST101-
KL17 originated from Serbia and Romania. When these putative
local expansions were excluded, the top 6 K loci were (KL24,
Fig. 3 Distribution of meropenem MIC, stratified by Kleborate-detected carbapenemase genes and OmpK35/36 porin mutations, for European K.
pneumoniae surveillance isolates. a Data shown summarize Kleborate results for 1490 K. pneumoniae genomes from the EuSCAPE study (data included in
Supplementary Data 2). Each circle represents the reported meropenem MIC for an isolate, coloured by type of porin mutation/s identified by Kleborate
from the corresponding genome assembly (colour key in inset legend, the prevalence of each genotype across 1490 genomes is indicated in brackets).
Isolates are stratified by carbapenemase gene (enzymes labelled on x-axis) and OmpK mutations41, 42 reported by Kleborate. Wt, full-length OmpK35 and
OmpK36 with no GD/TD insertion in the OmpK36 β-strand loop; mut, otherwise; Δ, missing/truncated. Dashed lines indicate EUCAST breakpoints for
clinical resistance (red, MIC > 8) and non-susceptibility (black, MIC > 2). For each boxplot, the length of the box corresponds to the interquartile range with
the centre line corresponding to the median, and the whiskers represent the minimum and maximum values. b Mean meropenem MIC values for the 1490
EuSCAPE isolates, grouped by the combination of porin gene status and the presence of carbapenemase genes. Porin status is expressed as: Δ, missing/
truncated; loop, GD or TD insertion in the OmpK36 β-strand loop; wt, otherwise.
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KL15, KL2, KL112, KL107, KL151) and accounted for just 34% of
the remaining genomes.
Global population snapshot of K. pneumoniae AMR and
virulence. We applied Kleborate to analyse n= 13,156 Klebsiella
genomes (see “Methods”, Supplementary Data 2). Here we pro-
vide a brief overview of the data followed by an exploration of
AMR, virulence and the phenomenon of convergence, with the
aim to highlight the rich information and types of inferences that
can be derived from Kleborate’s output.
The genome data represented isolates collected from a range of
sources in 99 countries between 1920–2020 (see Supplementary
Data 4, although human isolates from the USA, China and UK
dominated the data set accounting for n= 4702 genomes, 35.7%
of total). The majority of these genomes were sourced from
RefSeq, and among these Kleborate identified 1.0% (n= 103/
10,747) as a species other than the taxon recorded in NCBI; this is
consistent with other studies and highlights the current confusion
around taxonomic designations in Klebsiella. The most common
species was K. pneumoniae (n= 11,259, 86%); the rest comprised
other KpSC species (9.4%), other members of the K. oxytoca
species complex (3.1%) and K. aerogenes (1.9%) (Fig. 4,
Supplementary Data 4). AMR and virulence genes were
concentrated in the KpSC and particularly K. pneumoniae (Fig. 4,
Table 2).
The collection captured extensive phylogenetic diversity across
the K. pneumoniae species (see interactive phylogeny at http://
microreact.org/project/bQmTJfQmiCpFBjhoacaL8u), and Klebo-
rate assigned these genomes to ≥1452 different STs (1119 known
STs across and at least 333 novel STs). Notably, 600 STs (41%)
were represented by just a single genome each (accounting for
5.3% of all genomes). We detected n= 4 ST67 (subspecies
rhinoscleromatis) and n= 3 ST90 (subspecies ozanae). A small
number of STs were overrepresented, reflecting the bias towards
sequencing MDR and hypervirulent isolates, as well as those
causing hospital outbreaks. For example, 1354 genomes (12.0%)
represented the KPC-associated ST258, which is known to
dominate carbapenem-resistant K. pneumoniae in the USA and
southern Europe (where it has been the subject of intense genomic
investigations) but is comparatively rare in other regions of the
world16. To reduce the impact of these sampling biases in public
genome collections, we down-sampled to a non-redundant set of
9705 K. pneumoniae genomes representing unique combinations
of ST, genetic subcluster (Mash distance < 0.0003), virulence
genotype, AMR genotype, specimen type, location and year of
isolation (see “Methods”). However, we cannot fully correct for
the sampling biases inherent in the public genome data and even
after subsampling, the 30 most common STs accounted for 63.4%
of genomes (n ≥ 50 genomes each, n= 6151 total; see Supple-
mentary Fig. 5). Figure 5 shows the distribution of AMR and
virulence scores amongst non-redundant genomes from these 30
common K. pneumoniae STs (n > 50 per ST), each of which
displays high rates of AMR and/or virulence. Importantly, it also
highlights the high rates of AMR and/or virulence in some clones
(e.g. ST11, ST231), which may correspond to AMR-virulence
convergence within a single strain (see Facilitating detection of
AMR-virulence convergence section below).
AMR determinants. SHV β-lactamases conferring intrinsic resis-
tance to the penicillins were detected in 85.9% of the 9,705 non-
redundant K. pneumoniae genomes (ESBL forms of SHV were
detected in 10.0%). Acquired AMR was widespread









































































































0 1 0 0 0 0
10




































3 10 6 28 0 21 44 17 61 25 0 63 49 0 34
4 0 42 1 19 0 0 0






Fig. 4 Summary of genome collection metadata, and Kleborate-derived virulence and antimicrobial resistance (AMR) genotypes, for all publicly
available Klebsiella genomes. Data shown summarize Kleborate results for 11,277 non-redundant Klebsiella genomes publicly available as at 17 July 2020
(Supplementary Data 2). From left to right: barplots showing source information by geographical region and sample type (coloured as per inset legend);
heatmaps showing the prevalence of virulence loci (blue) and predicted AMR drug classes (red) (as per inset scale bars). Genomes are summarized by
species, ordered by species complex: KpSC, K. pneumoniae species complex; KoSC, K. oxytoca species complex; and other Klebsiella. In the heatmaps, the
total number of genomes in which each type of virulence/AMR determinant was detected are indicated below each column. Column names are as follows:
ybt yersiniabactin, clb colibactin, iuc aerobactin, iro salmochelin, rmp hypermucoidy Rmp, rmpA2 hypermucoidy rmpA2, AGly aminoglycosides, Col
colistin, Fcyn fosfomycin, Flq fluoroquinolone, Gly glycopeptide, MLS macrolides, Phe phenicols, Rif rifampin, Sul sulfonamides, Tet tetracyclines, Tgc
tigecycline, Tmt trimethoprim, Bla β-lactamases, inhR β-lactamase inhibitor, ESBL extended-spectrum β-lactamases, ESBL_inhR extended-spectrum β-
lactamase with resistance to β-lactamase inhibitors, Carb carbapenemase, Bla_chr intrinsic chromosomal β-lactamase, SHV mutations in SHV, Omp
truncations/mutations in ompK35/ompK36, Col truncations in mgrB/pmrB conferring colistin resistance, Flq mutations in gyrA/parC conferring resistance to
fluoroquinolones.
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acquired AMR detected) and 71.6% of genomes were predicted to
be MDR (acquired resistance to ≥3 drug classes50), a much higher
rate than is reported in most geographical regions3,51–53,
reflecting the bias within public genome collections. The majority
of genomes had a non-zero resistance score, reflecting the pre-
sence of ESBL and/or carbapenemase genes: 22.3%, 37.1% and
5.9% genomes had resistance scores of 1, 2 and 3 respectively.
Mean resistance scores increased through time (barplot in
Fig. 1b), and were correlated with the annual prevalence of ESBLs
(Spearman correlation coefficient rs= 0.80) and carbapenemases
(rs= 0.98) (line plots in Fig. 1b). This trend could be an artefact
of sampling bias towards the selective sequencing of AMR iso-
lates, however it is consistent with the increasing AMR rates
reported in surveillance studies globally54–56.
Comparatively higher prevalence of acquired AMR genes was
observed in some STs (Supplementary Fig. 5). Many of these STs
represent recognized MDR clones largely from clinical samples
that were also associated with high mean resistance scores
(Fig. 6a, b), driven by high frequency of ESBL and carbapenemase
genes (Fig. 5, Supplementary Fig. 6a, b). The most common
ESBLs/carbapenemases were widely detected across the popula-
tion (46-299 STs each), including amongst the top 30 common
STs (prevalence range per ST, 0.1–100%; see Supplementary Fig.
6a, b), highlighting their mobile nature. The notable exception
was CTX-M-65, which appeared to be largely clone-specific,
detected in only 9 STs and ST11 accounting for 96.7% of these
genomes.
Colistin resistance determinants57–59 were detected in 8.7% of
the non-redundant K. pneumoniae genomes. These were mostly
nonsense mutations in MgrB or PmrB (83.5%) rather than
acquisition of an mcr gene (15.8%, and an additional 6 genomes
with both acquired mcr and truncated MgrB/PmrB). The rate of
detection ranged from 0 to 25.2% for the 30 most common STs,
and was highest amongst ST512, ST437, ST147, ST16 and ST258
(Supplementary Fig. 6c), each of which are also associated with
high rates of carbapenem-resistance. Porin mutations were
detected in 37.9% of genomes (34.0% OmpK35, 20.2% OmpK36,
16.3% both). High prevalence of specific porin defects have been
reported previously in some clones41,42, and this was reflected in
our analysis of ST258 and its derivative ST512. We observed
OmpK35 truncations in 99.9% of non-redundant ST258 genomes
(with or without truncations or substitutions in OmpK36), and
truncations in OmpK35 and/or OmpK36 in all ST512 (99.4%
with OmpK35 truncations, 94.4% with the OmpK36GD muta-
tion, see Supplementary Fig. 6d).
Virulence loci. The prevalence of acquired siderophores and coli-
bactin loci amongst non-redundant K. pneumoniae genomes was
44.4% ybt, 7.5% clb, 11.2% iuc and 7.0% iro. The loci were found
across diverse K. pneumoniae STs (391 STs with ybt, 56 with clb,
144 with iuc, 108 with iro) but were rarely detected in other
Klebsiella species (with the exception of ybt among the K. oxytoca
species complex, see Fig. 4) indicating frequent mobilisation within
K. pneumoniae but not between species (Supplementary Data 5,
Table 2 Prevalence of virulence loci, ESBL and carbapenemase genes in non-redundant Klebsiella genomes.
















119 – 31, 26% 29, 24%
K. quasipneumoniae subsp.
similipneumoniae





K. quasivariicola 16 – 3, 19% –
K. africana 1 – – –





K. variicola subsp. tropica 18 – 2, 11% 1, 6%
K. oxytoca species
complex
K. oxytoca 98 Ybt: 96, 98% 9a, 9% 6, 6%
K. grimontii 75 Ybt: 41, 55% 1a, 1% 3, 4%
K. huaxiensis 4 – 1a, 25% –
K. michiganensis 144 Ybt: 102, 71% 21a, 15% 33, 23%
Clb: 1, 0.7%
K. pasteurii 21 Ybt: 21, 100% 1a, 5% –
K. spallanzanii 4 – –a –
NA K. aerogenes 209 Ybt: 101, 48% 24, 11% 34, 16%
Clb: 95, 45%
Iro: 190, 91%
K. indica 2 – – –
Ybt yersiniabactin, Clb colibactin, Iuc aerobactin, Iro salmochelin, Rmp hypermucoidy conferred by rmpADC locus.
aExcluding OXY genes that are conserved in K. oxytoca species complex.
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Supplementary Fig. 7). Mean virulence scores increased through
time (barplot in Fig. 1a) and were correlated with an annual pre-
valence of ybt (rs= 0.88), iuc (rs= 0.76) and rmp (rs= 0.62) (line
plots in Fig. 1a). Figure 5b shows the frequency of virulence scores
in the top 30 most common STs in the non-redundant genome set.
Sixteen of these common STs had ≥40% of genomes carrying the
ICEKp-associated ybt without the virulence plasmid-associated iuc
locus (i.e. virulence score= 1–2), including well-known MDR
clones ST258, ST11, ST14, ST15, ST101, ST147, ST152, ST395.
Only the hvKp clones (ST23, ST86, ST65) and ST231 had a high
frequency of iuc (virulence score ≥ 3).
In addition to detecting the presence of virulence loci,
Kleborate reports on their completeness, genetic lineages and
associated MGE variants, which can provide insights into their
dissemination. Most of the virulence loci identified in the non-
redundant K. pneumoniae data set (98%) matched one of the
genetic lineages described previously34,35 (Supplementary Data 5).
Supplementary Fig. 8a shows the frequency of iuc lineages in K.
pneumoniae STs with ≥20 non-redundant genomes and at least
one genome harbouring iuc. There were four STs for which >60%
genomes harboured iuc, and only a single iuc lineage was detected
in each (iuc1 in ST23, ST65, ST86; iuc2A in ST82), consistent
with the long-term persistence of a specific virulence plasmid in
these well-known hypervirulent clones. In contrast, iuc was less
frequent among other STs, several of which were associated with
multiple iuc lineages (e.g. ST231, ST25, ST35), consistent with
more recent and/or transient virulence plasmid acquisitions
(mostly iuc1, followed by iuc3 and iuc5).
Frameshift mutations (i.e. truncations) and/or incomplete loci
(i.e. missing at least one gene) were detected in 10%, 28.5%, 13.6%
and 17.7% of non-redundant K. pneumoniae genomes with ybt,
clb, iuc and iro respectively (Supplementary Data 6). While some
of these may erroneously arise from contig breaks in draft
genome assemblies, true truncations or missing genes may reflect
a lack of function. The latter is likely true for instances where we
observe conserved frameshift mutations across entire lineages, e.g.
frameshift mutations were detected in iucA for all iuc3+ genomes
and in iroC for all iro3+ and iro4+ genomes.
The hypermucoidy locus rmpADC was detected in 8.4% of
non-redundant K. pneumoniae genomes (and just eight genomes
of other KpSC species, Supplementary Data 5). The majority of
these genomes (67.2%, belonging to >79 STs) carried intact copies
of all three genes, thus likely express the hypermucoid phenotype.
Intact rmpADC was common in iuc-positive genomes of the
hvKp clones ST23 and ST86, as well as MDR clones ST29 and
ST101 (Supplementary Fig. 8b). Many other iuc-positive genomes
carried rmpADC loci with truncated or missing genes, which
likely do not confer the hypermucoid phenotype. Notably, these
included hvKp clones ST65 and ST82, as well as MDR clones
ST231, ST15 and ST14. The rmpA2 gene was detected in 7.4% of
non-redundant K. pneumoniae genomes, but was mostly present
in truncated form (89.0% of rmpA2+ genomes) due to frame-
shifts within a poly-G tract60. The latter highlights the
importance of considering not only the presence/absence of a
given gene, but also whether it encodes a full-length protein,
which may have important clinical implications.
Facilitating detection of AMR-virulence convergence. AMR
and virulence determinants have until recently been segregated in
non-overlapping K. pneumoniae populations14,19, as clearly
indicated by the distributions of AMR and virulence scores
among STs (Figs. 5, 6a). However, reports of convergent AMR-
virulent strains with the potential to cause difficult-to-treat
infections are increasingly common16,61. Kleborate facilitates
rapid identification of such strains on the basis of resistance and
virulence scores (convergence defined as virulence score ≥3 and
resistance score ≥1, Fig. 6c). Based on these scores, we observed a
total of 601 convergent K. pneumoniae (510 non-redundant) with
the highest proportion corresponding to a virulence score of 4
(indicative of yersiniabactin plus aerobactin/virulence plasmid
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Fig. 5 Distribution of (a) resistance and (b) virulence scores among genomes belonging to the 30 most common K. pneumoniae lineages. Data shown
summarize Kleborate results for non-redundant set of 9705 publicly available K. pneumoniae genomes (Supplementary Data 2). Lineages were defined on
the basis of multi-locus sequence types (STs) reported by Kleborate, and ordered from highest to lowest difference between mean virulence and mean
resistance score. Minimum genome count per ST shown is 50. Ybt yersiniabactin, clb colibactin, iuc aerobactin, VP virulence plasmid, ESBL extended-
spectrum β-lactamase, Carb carbapenemase, Col colistin resistance determinant.
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The majority of convergent genomes (74.5%) were concentrated
within a small number of STs comprising well-known hypervirulent
(e.g. ST23, ST86, ST65) or MDR lineages (e.g. ST11, ST15, ST231
and ST147) (Figs. 6c, d, 7). Using the combination of genotyping
data and a Mash-distance-based neighbour-joining tree (http://
microreact.org/project/JDyan46yctyDh6weEUjWN) we identified
174 unique convergence events (Supplementary Data 7, see
“Methods” for details). The majority of convergence events (n=
95, 55%; 137 genomes) were attributed to the acquisition of AMR in
strains already carrying iuc (including 65 events (37.4%) corre-
sponding to the acquisition of AMR by known hypervirulent clones;
see Fig. 7, Supplementary Data 7). A further 67 events (38.5%; 449
genomes) were attributed to the acquisition of iuc in strains already
carrying ESBLs/carbapenemases, and for 12 events (15 genomes)
the order of acquisition could not be resolved.
The most common virulence plasmid, KpVP-1 (iuc1 ± iro1),
accounted for 63% of virulence plasmid acquisition events (n=
42 acquisitions), while iuc3 plasmids, the E. coli derived iuc5
(±iro5) and iuc/iro unknown (i.e. novel or divergent iuc/iro loci)
accounted for 8%, 13% and 16%, respectively (Fig. 7). AMR
acquisitions by hypervirulent clones involved the ESBL/carbape-
nemase genes that are most common in the general K.
pneumoniae population: KPC-2 (24%), OXA-232 (17%) and
CTX-M-15 (16%). The majority of convergence events (87%)
were associated with just a small number of genomes (i.e. n ≤ 3);
however, five events were associated with >20 genomes in the
ST20























































































































































Fig. 6 Insights from resistance and virulence scores. Data shown summarize Kleborate results for non-redundant set of 9,705 publicly available K.
pneumoniae genomes (Supplementary Data 2). a–b Mean resistance and virulence scores grouped by (a) lineage and (b) sample type. Each circle
represents a single lineage (multi-locus sequence type, ST) or sample type as labelled; size indicates the number of genomes (as per inset legend); colour
indicates groups per inset legend. c Heatmap showing number of genomes with each combination of resistance and virulence scores. Convergent genomes
correspond to a virulence score ≥3 (carrying iuc) and resistance score of ≥1 (carrying ESBL and/or carbapenemase gene/s), as indicated by the red box.
d Barplots showing lineage distribution of convergent genomes, for each combination of resistance score and virulence score. Lineages are grouped into
hypervirulent (hv), multidrug resistant (MDR) and others; and coloured by ST (as per inset legend).
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complete dataset, which may indicate clonal expansion and
dissemination of the corresponding convergent strains locally
and/or between countries. One such event corresponded to the
ST11-KPC+ KpVP-1 deletion variant strain that was originally
reported in 201720 and has since been recognized as widely
distributed in China20–24. The complete public genome set (i.e.
counting redundant genomes) included 148 genomes corre-
sponding to this specific ST11 convergence event mostly from
China but also from France (n= 2). Notably though, this was
only one of 50 convergence events that we detected in China,
including 8 involving the acquisition of iuc1 or iuc5 by ST11 (see
Supplementary Data 7, and interactive tree at http://microreact.
org/project/JDyan46yctyDh6weEUjWN). Additional events asso-
ciated with >20 genomes included (i) ST231-MDR+ virulence
plasmids carrying novel iuc lineages detected in India, Pakistan,
Switzerland, Thailand and USA, (ii) ST15-CTX-M-15+ KpVP-1
in Pakistan, (iii) ST15-MDR+ KpVP-1 in China and Nepal, and
(iv) another distinct ST11-KPC-2+KpVP-1 event in China.
Including the above three examples, 11 convergence events
appeared to involve intercountry expansion of which one has
been previously documented62.
Overall, convergent genomes were detected originating from
most geographical regions for which genome data was available,
but some regions had many more events than others (Fig. 7,
Supplementary Data 7). This uneven distribution may stem from
a skew in the number of genomes available per region (e.g. due to
variation in accessibility or application of genome sequencing).
Nevertheless, the number of convergent genomes in the eastern,
southeastern and southern parts of Asia were noticeably high,
driven by the frequency of convergence events detected in China
(n= 50 events) and Thailand (n= 26 events) as well as putative
clonal expansions of these strains as discussed above (Fig. 7). Of
note, AMR acquisitions by hypervirulent lineages were particu-
larly frequent within East and Southeast Asia where hypervirulent
infections are most frequently reported, alongside countries from
eastern and northern Europe.
Outside of K. pneumoniae, convergence events were rare: we
detected n= 2 K. quasipneumoniae subsp. similipneumoniae
(ST367 with KpVP-1 and CTX-M-15; ST3387 with iuc3 and
CTX-M-55) and n= 2 K. variicola subsp. variicola (ST595 with
KpVP-1 and KPC-2; ST1848 with iuc5 and KPC-2).
Genotyping K. pneumoniae from metagenome data. There is
increasing interest in detection and typing of K. pneumoniae
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Fig. 7 Convergence of AMR and virulence determinants in the K. pneumoniae population, identified by Kleborate analysis of public genomes.
a Geographical and lineage distribution of convergence events. Each circle represents a unique convergence event (i.e. a monophyletic clade harbouring
both ESBL/carbapenemase genes and iuc; see interactive tree at https://microreact.org/project/JDyan46yctyDh6weEUjWN, summary of events in
Supplementary Data 7, assignment of genomes to events in Supplementary Data 2). Circles are scaled by the number of total genomes linked to the event
and coloured to indicate whether convergence is inferred to have occurred via (i) acquisition of AMR gene/s (ESBL or carbapenemase/s) by a
hypervirulent lineage, (ii) acquisition of an iuc-encoding plasmid by an AMR or non-AMR lineage, or (iii) unresolved means as per inset legend. Marginal
barplots show the number of convergence events (colour blocks) and genomes (block heights) associated with each lineage (top) or geographical region
(right). Lineages were defined on the basis of multi-locus sequence types (STs), number of convergence events estimated for each is labelled at the top of
each bar. b Distribution of convergent genomes by location. Countries from which convergent genomes were detected are coloured on the map; circles
represent the number of convergent genomes detected in each UN-defined geographical region (indicated by colour, as per inset legend), scaled and
labelled with the minimum estimated number of unique convergence events specific to each region (excluding inter-regional convergence events). The
total number of convergence events affecting each region, including region-specific and inter-regional convergence events, are given in brackets in the inset
legend.
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pneumoniae gut colonization as a source of acute infections and
as a contributor to chronic diseases7,8. We tested Kleborate’s
performance by application to n= 40 metagenomes from which
at least one KpSC isolate was cultured and sequenced, as part of
the Baby Biome Study64. We compared the results of running
Kleborate on metagenome-assembled genomes (MAGs, i.e.,
species-specific contig bins extracted from whole-metagenome
assemblies) vs. KpSC isolate whole-genome sequence(s) cultured
from the same fecal sample. Thirty-two metagenomes had >1%
relative abundance of KpSC, and genotyping of MAGs from these
yielded results consistent with genotyping of cultured isolates for
26/32 samples (16 with identical genotypes reported for species,
ST, K/O locus, virulence and AMR; 10 with close matches; see
Supplementary Fig. 8, Supplementary Data 8–9). As expected,
MAG-derived genotypes were closest to those of isolates when
only one KpSC strain was cultured from the sample (see Sup-
plementary Fig. 8, Supplementary Data 9). We were unable to
assess the reliability of Kleborate for distinguishing KpSC from
non-KpSC Klebsiella in a single metagenome sample, as there
were no samples with sufficient abundance of both KpSC and
non-KpSC species to yield the corresponding MAGs for both (i.e.
in the n= 9 samples for which both KpSC non-KpSC were iso-
lated, the relative abundance of one species or the other was too
low to yield a corresponding MAG). Kleborate analysis of whole
metagenome assemblies (as opposed to individual MAGs) is not
recommended: species detection and ST assignment matched that
of the corresponding WGS isolates for only n= 4/40 metagenome
assemblies, which is unsurprising as the whole metagenomes
include sequences derived from dozens of different bacteria,
many of which harbour homologs of genotyping targets.
Discussion
WGS is being increasingly implemented in research and public
health labs as a cost- and time-effective option for tracking
pathogens and AMR determinants. However, the identification
of known clinically relevant features remains a key bottleneck
that hinders widespread adoption of genome surveillance. We
have presented a comprehensive framework and tool for rapid
genotyping of Klebsiella species genomes: Kleborate is a single
unified approach for species detection, MLST and genotyping
of key virulence and AMR determinants. It focuses only on
genomic features for which there is strong evidence of a clini-
cally relevant phenotype in KpSC and presents the data in a
readily interpretable format, with numerical summaries and
categorical scores corresponding to measures of potential
clinical risk. While there is generally high concordance between
genotypes and phenotypes (e.g. AMR gene detection is typically
predictive of phenotype65–69), Kleborate reports only genotypes
and does not provide predictions of clinical antibiotic resistance
or virulence. It is also important to note that in some instances,
accurate phenotypic predictions may not be possible given the
complexities in the underlying genetic mechanisms that are not
yet fully understood (e.g. the interactions of specific carbape-
nemases and OmpK variants and how these contribute to MIC
for carbapenems).
A key strength of the Kleborate framework is its species-
specific approach. This is particularly important for accurate
interpretation of AMR and virulence gene screens from WGS,
wherein the use of generic databases and tools can result in
confusion. Notable examples include the intrinsic oqxAB and fosA
alleles, which unlike for other Enterobacterales, do not confer
resistance to quinolones and fosfomycin when expressed in
KpSC. Kleborate does not report these intrinsic alleles, neither
does it report intrinsic virulence determinants such as the side-
rophore enterobactin, which is known to play a role in KpSC
pathogenicity but for which the presence alone cannot be con-
sidered to indicate enhanced virulence of one isolate over
another. Correct taxonomic identification of K. pneumoniae can
be difficult in itself, hence the inbuilt speciation tool is an
important feature (and here identified nearly 100 RefSeq genomes
with incorrect species/subspecies assignments).
Another strength of our approach is the rich data output by
Kleborate, which facilitates in-depth investigation of population
structure, AMR and virulence epidemiology. This allows rapid
exploration and understanding of (i) hypervirulence-associated
loci and the molecular drivers of their dissemination (Supple-
mentary Figs. 5 and 8); (ii) molecular mechanisms of complex
AMR phenotypes e.g. carbapenem resistance (Fig. 3); (iii) AMR
and virulence trends (Figs. 1, 5 and 6); (iv) emerging convergent
AMR-virulent strains so that they can be targeted for surveillance
and infection control (Fig. 7); (v) overrepresented STs and gen-
otypes, which may be indicative of transmission clusters that
should be targeted for further investigation (as demonstrated for
the EuSCAPE surveillance genomes, Fig. 2a); (vi) surface antigen
epidemiology, which can inform the design of novel vaccines and
therapeutics (Fig. 2b, c). Notably Kleborate can also yield useful
genotyping results from metagenomics data (Supplementary Fig.
9), which is gradually being adopted for clinical and surveillance
applications relevant to K. pneumoniae. User interpretation of
Kleborate’s extensive data output can be guided by the accom-
panying web-based visualization app, Kleborate-Viz. Through
this app, many of the analyses and plots presented in this
manuscript can be rapidly replicated, and further explored in an
interactive manner.
Kleborate is designed to facilitate detection and tracking of
clinically relevant AMR and virulence determinants from genome
data, and analysis of public data not only identified specific clones
and genes associated with one or the other of AMR and virulence
(Figs. 5, 6), but also 601 genomes in which the two converge
(carrying iuc+ virulence plasmids and ESBL and/or carbapene-
mase genes; Fig. 7). We estimated at least 174 unique AMR-
hypervirulence convergence events; the majority were detected
within a single isolate (n= 121 events), but many others appear
to be associated with local outbreaks or larger-scale spread and
apparently across multiple countries (Supplementary Data 7).
Some of the convergence events in China and other countries in
the neighbouring South and Southeast Asia regions have been
extensively reported16,20,51,61, but to our knowledge, a significant
number had not been recognized previously. These include
ST231-MDR (most with OXA-232, remainder with ESBL only) +
iuc, which has been reportedly circulating in India51, and our
analysis also detected in Pakistan, Thailand, Switzerland
and USA.
Kleborate has already been widely adopted by the Klebsiella
research community—at least 74 studies have reported using the
Kleborate software package, including larger-scale genome sur-
veillance studies in South and Southeast Asia, the Caribbean and
the United States31,51,52 (full list in Supplementary Data 10).
Kleborate is freely available as a standalone command-line tool
for local high-throughput analyses or incorporation into existing
bioinformatics workflows (https://github.com/katholt/Kleborate),
and can be easily accessed through the online tool Pathogenwatch
(https://pathogen.watch/). With such broad accessibility and
utility, Kleborate is poised to become a cornerstone of the Kleb-
siella genomic surveillance toolkit that can help inform contain-
ment and control strategies targeting this priority pathogen. Input
will be sought from the Klebsiella and AMR surveillance com-
munities to guide ongoing development, including establishing
formal criteria for inclusion of AMR or virulence features and
improving reporting of results.
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Methods
Kleborate software: implementation and genotyping logic. Kleborate (v.2.0.0) is
a command-line tool written in Python and is freely available under the GNU v3.0
license at http://github.com/katholt/Kleborate. It takes as input one or more whole-
genome assemblies (FASTA format), types each one against a series of screening
databases outlined in detail below, and returns results in a tab-delimited text file
(one genome per row). On default settings, Kleborate will report assembly quality
metrics, taxonomic assignment, MLST and virulence loci genotypes. Screening for
AMR determinants, and/or K/O serotyping via Kaptive36, is optional (Table 1).
Assembly quality. Assembly quality metrics, reported to help users assess the
reliability of genotyping results, are: contig count, contig N50, largest contig size,
total genome size, and number of ambiguous bases (e.g. ‘N’). Low-quality warnings
are flagged if (i) ambiguous bases are detected; (ii) assembly length falls outside the
expected range of 4.5–7.5 Mbp; or (iii) N50 is below 10,000 bp. Users should
carefully consider the genotyping outputs for low-quality assemblies.
Taxonomic assignment. Kleborate’s species prediction function provides a con-
venient way to confirm species, including differentiating between the closely related
members of the KpSC which are frequently misclassified using laboratory techni-
ques. Kleborate calculates Mash40 distances between the input genome/s and a
curated collection of reference assemblies from different Klebsiella and other
Enterobacterales, and reports the species with the smallest distance. Mash distance
≤0.02 is reported as a strong match, ≤0.04 as weak (only when no strong matches
are found, see Supplementary Note 1 for further details).
MLST. Genomes assigned to species in the KpSC are assigned STs using nucleotide
BLAST against the established K. pneumoniae chromosomal seven-locus MLST
scheme29 described and maintained on the K. pneumoniae BIGSdb site hosted at
the Pasteur Institute (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html).
Virulence gene detection and typing. Virulence loci (ybt, iuc, iro, clb, rmpADC,
rmpA2) are detected using nucleotide BLAST search against the database of known
alleles. The best hit allele for each gene (with ≥90% identity and ≥80% coverage) is
reported in the main virulence columns. If the majority of genes expected for the
locus are present, then the alleles are used to calculate STs which are reported along
with their associated lineage and MGE (based on previously defined schemes: YbST
for ybt, CbST for clb, AbST for iuc, SmST for iro, according to the previously
defined schemes34,35; and a novel RmST scheme for the rmpADC locus). To
generate the RmST typing scheme we used the same 2733 genomes from our
original virulence plasmid study35 to screen and extract the sequences for rmpADC
and define allele numbers and STs. These ST sequences cluster into four distinct
lineages associated with distinct MGEs (rmp1 with KpVP-1, rmp2 with KpVP-2,
rmp2A with the iuc2A virulence plasmids, and rmp3 with ICEKp1; to be described
in detail elsewhere). Where the best hit for a gene is a weak match (80–90%
identity, 40–80% coverage) this is reported in the ‘spurious hits’ column. Trun-
cations are detected by translating the best-matching nucleotide sequence for each
query gene into amino acids and comparing to the reference length (expressed as %
amino acid length from the start codon, those <90% are reported).
The presence of ybt, clb and iuc are used to assign a virulence score as follows: 0
= none present, 1= yersiniabactin only, 2= colibactin without aerobactin
(regardless of yersiniabactin, however, ybt is almost always present when clb is), 3
= aerobactin only, 4= aerobactin and yersiniabactin without colibactin, and 5= all
three present. The presence of iro (salmochelin) is not used to calculate the
virulence score because its presence is very strongly associated with aerobactin. The
scoring aims to capture the general hierarchy of virulence and associated loci that
have emerged from the literature over the last two decades. Yersiniabactin
facilitates immune escape (by evading Lcn2) and has been shown to increase
virulence in multiple strain backgrounds70, however it is not associated with
toxinogenic activity (like clb71) or growth in blood (like iuc72). Ybt is also the most
common virulence determinant (~20–50% of clinical isolates) and is almost always
present in clb+ isolates (clb is carried by one of the 14 forms of the yersiniabactin
ICE described to date34) and in isolates carrying the virulence plasmid16,35; hence
the presence of yersiniabactin is assigned a score of 1. The next increment in score
(2) is assigned to the presence of the genotoxin clb in addition to ybt, because of
clb’s genotoxic activity against mammalian cells71 but there is only limited evidence
that it elevates virulence substantially in the absence of the virulence plasmid. A
recent study evaluating markers of hypervirulence identified the K. pneumoniae
virulence plasmid markers (iuc, iro, rmpA, rmpA2, peg-344) as being highly
diagnostic of hypervirulent vs classical K. pneumoniae infection amongst human
clinical isolates, and are also predictive of mortality in a murine sepsis model73.
These virulence plasmid markers are in very strong genetic linkage (~99%), hence
in principle any of these would serve as a good marker for the next increment in
virulence score; however, we selected iuc as it is the most clearly and directly
functionally related to sepsis (promoting growth in blood via the acquisition of
iron from transferrin72,74). While there is limited data with which to assess the
individual contributions of ybt, clb and the virulence plasmid when present in
combination, it is logical to score iuc+ ybt higher than iuc without ybt. In the well-
described hypervirulent clone ST23, the most widely distributed sublineage that is
responsible for the majority of liver abscess documented globally (CG23-I) is
distinguished by carrying clb, compared to the rest of the ST23 population which
carries clb- ICEs and are rarely seen75; hence we assign the presence of iuc
(virulence plasmid) + ybt+ clb as the highest score.
Detection and typing of antimicrobial resistance determinants. When AMR detec-
tion is switched on, Kleborate screens for known acquired AMR determinants using
a curated version of the CARD AMR nucleotide database (v3.0.8 downloaded
February 2020; see doi.org/10.6084/m9.figshare.13256759.v1 for full details on
curation). Genes are identified using nucleotide BLAST (and amino acid search with
tBLASTx if no exact nucleotide match is found). Gene truncations and spurious hits
are identified as described above for virulence genes. Unlike the acquired forms, the
intrinsic variants of oqxAB, chromosomal fosA and ampH are not associated with
clinical resistance in KpSC and are therefore not reported. However, SHV, LEN or
OKP β-lactamase alleles intrinsic to KpSC species are known to confer clinical
resistance to penicillins and are reported in the Bla_chr column. Acquired SHV
variants, and individual SHV sequence mutations known to confer resistance to
extended-spectrum β-lactams or β-lactamase inhibitors, are reported separately (see
Supplementary Note 3, Supplementary Data 11 and 12 for details).
Chromosomally encoded mutations and gene loss or truncations known to be
associated with AMR are reported for genomes identified as KpSC species. These
include fluoroquinolone resistance mutations in GyrA (codons 83 and 87) and
ParC (codons 80 and 84)76, and colistin resistance from truncation or loss of MgrB
and PmrB57–59 (defined as <90% amino acid sequence coverage). Mutations in the
OmpK35 and OmpK36 osmoporins reportedly associated with reduced
susceptibility to β-lactamases41,42 are also screened and reported for KpSC
genomes, and include truncation or loss of these genes and OmpK36GD and
OmpK36TD transmembrane β-strand loop insertions41. SHV β-lactamase, GyrA,
ParC and OmpK mutations are identified by alignment of the translated amino
acid sequences against a reference using BioPython, followed by an interrogation of
the alignment positions of interest (see Supplementary Note 3, Supplementary
Data 11 and 12 for a list of relevant positions).
AMR genes and mutations are reported by drug class, with β-lactamases further
categorized by enzyme activity (β-lactamase, ESBL or carbapenemase, with/without
resistance to β-lactamase inhibitors). Horizontally acquired AMR genes are
reported separately from mutational resistance and contribute to the AMR gene
count; these plus chromosomal mutations count towards the number of acquired
resistance classes (intrinsic SHV alleles, reported in Bla_chr column, are not
included in either count). Resistance scores are calculated as follows: 0= no ESBL
or carbapenemase, 1= ESBL without carbapenemase (regardless of colistin
resistance); 2= carbapenamase without colistin resistance (regardless of ESBL);
3= carbapenemase with colistin resistance (regardless of ESBL).
Serotype prediction. By default, genomes are screened against the wzi database in
the Klebsiella BIGSdb (using nucleotide BLAST) which is used to predict capsule
(K) type based on a previously defined scheme77. This allows rapid typing however
the relationship between wzi allele and K type is not one-to-one36. If surface
antigen prediction is important to users they can obtain more robust identification
of K and O antigen (LPS) loci by switching on serotype prediction with Kaptive36
(—kaptive), which adds a few minutes per genome to Kleborate’s runtime.
Data visualization. To facilitate interpretation of Kleborate’s rich data output we
provide a web-based application (Kleborate-Viz, https://kleborate.erc.monash.edu/),
implemented in R Shiny, which takes as inputs a Kleborate results file (required),
sample metadata (CSV format, optional) and MIC data (CSV format, optional).
User data is temporarily stored on the server for the duration of the session and is
immediately deleted when the session is terminated upon closing the browser
window or tab.
Genome analysis. The analyses reported here result from applying Kleborate
v2.0.0 (doi:10.5281/zenodo.4923015) to publicly available genome collections. A
total of 13,156 Klebsiella WGS assemblies, encompassing non-duplicate isolates
with unique BioSample accessions identified from published studies (some
deposited as read sets only, which were assembled using Unicycler v0.4.778, data
sources summarized in Supplementary Data 13) plus any additional genomes
designated as Klebsiella in NCBI’s RefSeq repository of genome assemblies (as of 17
July 2020). In order to minimize the impact of sampling bias favoring common
MDR and/or virulent lineages and those causing outbreaks, we subsampled the
collection into a ‘non-redundant’ dataset of 11,277 genomes (9705 K. pneumoniae)
as follows. Pairwise Mash distances were calculated using Mash v2.1, and used to
cluster genomes using single-linkage clustering with a threshold of 0.0003. These
clusters were further divided into non-redundant groups with unique combinations
of (i) Mash cluster, (ii) chromosomal ST, (iii) virulence gene profiles (i.e. presence
of ybt/clb/iro/iuc loci and lineage assignment), (iv) AMR profiles, (v) year and
country of isolation, and (vii) specimen type where available. For each resulting
non-redundant group, one genome was selected at random as the representative for
analyses. The full list of genomes, including database accessions, isolate informa-
tion, cluster/group assignment, and Kleborate results are provided in Supple-
mentary Data 2. The subset of 1624 K. pneumoniae assemblies deposited in RefSeq
by the European EuSCAPE surveillance study33 (out of 1649 reported in original
study; Supplementary Data 2) were used for the EuSCAPE analyses reported in
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Figs. 2 and 3. The Kleborate-Viz web application is pre-loaded with the non-
redundant and EuSCAPE WGS datasets reported in this paper, and can be used to
reproduce the plots shown in Figs. 1a–c, 2b, c, 3, 6a, b and to further explore the
Kleborate results.
Analysis of AMR-virulent convergent genomes. The Mash-distance-based
neighbour-joining tree (https://microreact.org/project/JDyan46yctyDh6weEUjWN)
was used to identify unique subtrees of AMR-virulent convergent genomes (i.e.
carrying iuc plus an ESBL and/or carbapenemase gene), which revealed 174 unique
clusters representing independent convergence events. The majority of these were
within known hypervirulent (n= 65) or MDR clones (n= 57; see Supplementary
Data 7); for these the order of acquisition was trivially assigned as virulence then
resistance, or resistance then virulence, respectively. For the remaining n= 52
events, the distribution of resistance and iuc genes in each subtree and its sister
clades was manually inspected by two independent analysts to infer the order of
acquisition based on the maximum parsimony principle. In 12 cases, the order of
virulence vs. AMR acquisition could not be resolved (see Supplementary Data 7).
Metagenome analysis. We downloaded metagenomic reads, and matched isolate
WGS assemblies, for n= 47 infant gut microbiota samples deposited by the Baby
Biome Study64. Metagenome reads were assembled using SPAdes version 3.13.179
with the --meta flag and the resulting contigs binned using MaxBin v2.2.780. Seven
metagenomes failed to assemble due to memory and compute walltime constraints,
hence we report results for 40 samples (Supplementary Data 9). Kleborate was run
separately on the full metagenome assemblies, all contig bins (from which the
Klebsiella bin could then be identified), and the matched WGS assemblies. Meta-
genomic read sets were also analysed using Kraken 2.0.781 and Bracken v2.582
(with a custom GDTB release 89 database83) to estimate the relative abundance of
KpSC reads in each metagenome.
Statistical analysis. Statistical analyses and data visualisations were conducted
using R v1.1.456. Figures were generated with ggplot v3.2.0 and pheatmap v1.0.12.
Correlations between virulence and resistance scores, and the prevalence of viru-
lence and resistance determinants over time, were analysed using Spearman’s rank-
order correlation (i.e. non-parametric test).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Supplementary Data 2 lists accession numbers for each genome analyzed in this study,
alongside the isolate collection metadata where available and Kleborate-generated output.
An interactive phylogeny of all public Klebsiella genomes alongside (i) the corresponding
Kleborate data or (ii) information relating to convergence events can be accessed at (i)
http://microreact.org/project/bQmTJfQmiCpFBjhoacaL8u and (ii) https://microreact.
org/project/JDyan46yctyDh6weEUjWN respectively. Supplementary Data 8 lists
accession numbers for metagenome reads, matched isolate whole-genome assemblies and
the Kleborate-generated output.
Code availability
The code and detailed instruction manuals for running Kleborate and Kleborate-Viz can
be found at http://github.com/katholt/Kleborate and https://kleborate.erc.monash.edu/
respectively. The code for Kleborate v2.0.0 used in the study can be found at doi:10.5281/
zenodo.492301584.
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